Update shared on04 Sep 2025
With Daiichi Sankyo's net profit margin and future P/E multiples both effectively unchanged, analysts have maintained their consensus price target at ¥5459.
What's in the News
- DATROWAY (datopotamab deruxtecan) approved in China for HR positive, HER2 negative breast cancer after prior endocrine and chemotherapy, jointly developed with AstraZeneca.
- ENHERTU (trastuzumab deruxtecan) approved in Japan for HR positive, HER2 low/ultralow unresectable or recurrent breast cancer; based on positive DESTINY-Breast06 phase 3 results but carries an interstitial lung disease warning.
- Ifinatamab deruxtecan (I-DXd) granted Breakthrough Therapy Designation by FDA for extensive-stage small cell lung cancer after platinum-based chemotherapy, and is being developed across multiple B7-H3 targetable cancers.
- ENHERTU in combination with pertuzumab granted FDA Breakthrough Therapy Designation for first-line treatment of unresectable or metastatic HER2 positive breast cancer, based on positive DESTINY-Breast09 phase 3 data.
- Datroway approved in the US for EGFR-mutated NSCLC after EGFR therapy and platinum chemo, with confirmed ORR of 45% and median DoR of 6.5 months in TROPION-Lung trials.
Valuation Changes
Summary of Valuation Changes for Daiichi Sankyo Company
- The Consensus Analyst Price Target remained effectively unchanged, at ¥5459.
- The Net Profit Margin for Daiichi Sankyo Company remained effectively unchanged, at 16.85%.
- The Future P/E for Daiichi Sankyo Company remained effectively unchanged, at 24.09x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.